SOURCE: Leerink Swann & Company

June 30, 2005 06:00 ET

Leerink Swann & Company Initiates Coverage of Medicis Pharmaceutical Corporation (NYSE: MRX)

BOSTON, MA -- (MARKET WIRE) -- June 30, 2005 -- Yesterday after the close, Senior Specialty Pharmaceuticals Analyst, Gary Nachman, initiated coverage of Medicis Pharmaceuticals Corporation with an Outperform rating. His investment rating is based on the successful outcome of the proposed merger with Inamed Corporation, which he believes would increase the company's exposure to the high-growth cosmetics market. Mr. Nachman views the merger as a strategically smart move for Medicis because it should help drive significant long-term growth at the combined company.

About Medicis Pharmaceutical Corporation

Medicis Pharmaceutical Corporation (NYSE: MRX) is a specialty pharmaceutical company focusing primarily on the treatment of dermatological aesthetic, and podiatric conditions. Medicis offers prescription products for the treatment of acne, eczema, rosacea, and psoriasis as well fine lines and wrinkles. The company is headquartered in Scottsdale, Arizona.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564